STAT

Most people pay less than $5 per month for the drug. But some pay $11,002

We looked at the websites pharma companies made to share drug pricing info — and there are some jarring numbers in the fine print.

A version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

WASHINGTON — “Most* patients pay between $0 and $5 per month” for Janssen’s drug Stelara, the chart proclaims.

But, boy, does that asterisk contain quite the caveat. Way down at the other end of the graphic, any patient paying the list price is shelling out a whopping $11,002 every month for the same drug.

The jarring figure comes from a new Janssen website launched recently as part of the broader pharmaceutical industry’s push to disclose some pricing information in its television ads. A broad swath of

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks